873 ISM5939, a novel, potent, orally available, selective ENPP1 inhibitor enhances the anti-tumor effects of immune checkpoint inhibitors in syngeneic murine cancer models
Main Authors: | Man Zhang, Jin Liu, Celia Chen, Xin Cheng, Feng Ren, Jianyu Wu, Luoheng Qin, Supriya Bavadekar, Sujata Rao, Alex Zhavoronkov |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
Identification of novel pyrrolopyrimidine and pyrrolopyridine derivatives as potent ENPP1 inhibitors
by: Hee Jin Jeong, et al.
Published: (2022-12-01) -
ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors—A STING in the Tale of ENPP1
by: Kenneth I. Onyedibe, et al.
Published: (2019-11-01) -
Enpp1 enzyme replacement restores bone mass in murine model of Enpp1 associated osteoporosis
by: Demetrios Braddock, et al.
Published: (2020-10-01) -
897-G SR-8541A, a small molecule inhibitor of ENPP1, enhances the effect of immune checkpoint inhibitors in a colorectal cancer model
by: Sunil Sharma, et al.
Published: (2023-11-01) -
A novel small molecule Enpp1 inhibitor improves tumor control following radiation therapy by targeting stromal Enpp1 expression
by: Jason R Baird, et al.
Published: (2024-12-01)